Dec. 20, 2013 (Life Technologies Press Release) -- Life Technologies Corporation (NASDAQ: LIFE) today announced that Cynvenio Biosystems, a molecular testing company focused on liquid biopsy assay development, has joined the Ion Certified Service Provider (CSP) program. Cynvenio’s LiquidBiopsy® technology is a proprietary platform for recovering circulating tumor cells at purity levels high enough to enable detection by next-generation sequencing.
Service providers in the Ion CSP program are reviewed and qualified for membership by Life Technologies based on rigorous quality standards. In addition to providing research-use-only (RUO) services under the Ion CSP program, Cynvenio has several development programs supported by the National Cancer Institute that are focused on finding cancer biomarkers in the blood. These programs are aimed at developing fast, non-invasive methods for detecting and managing breast cancer and other adenocarcinomas (solid tumors).
Read full press release at www.lifetechnologies.com.